MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
February 24, 2011
Brian Orelli
Continuing to Play Me-Too Onglyza is never going to catch Januvia. mark for My Articles similar articles
The Motley Fool
May 18, 2011
Brian Orelli
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. mark for My Articles similar articles
The Motley Fool
October 28, 2011
Brian Orelli
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. mark for My Articles similar articles
The Motley Fool
July 29, 2011
Brian Orelli
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. mark for My Articles similar articles
The Motley Fool
September 9, 2008
Brian Orelli
Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment. mark for My Articles similar articles
The Motley Fool
April 28, 2011
Brian Orelli
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. mark for My Articles similar articles
The Motley Fool
April 3, 2007
Brian Lawler
Merck Gets the Combo Merck gets marketing approval for a diabetes combination drug. Investors, take note. mark for My Articles similar articles
The Motley Fool
September 30, 2011
Brian Orelli
A Drug Market That's 366 Million Strong Diabetes drugs have potential. mark for My Articles similar articles
The Motley Fool
May 17, 2011
Luke Timmerman
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. mark for My Articles similar articles
The Motley Fool
October 22, 2008
Brian Orelli
Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013. mark for My Articles similar articles
The Motley Fool
September 28, 2009
Brian Orelli
Here We Go Again With Possible Side Effects The FDA says it has received 88 reports of pancreatitis in patients taking Merck's Januvia and Janumet. mark for My Articles similar articles
The Motley Fool
July 7, 2011
Brian Orelli
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. mark for My Articles similar articles
The Motley Fool
July 23, 2007
Brian Lawler
Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition. mark for My Articles similar articles
The Motley Fool
June 26, 2009
Brian Orelli
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. mark for My Articles similar articles
The Motley Fool
August 4, 2010
Brian Orelli
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. mark for My Articles similar articles
The Motley Fool
October 23, 2006
Brian Lawler
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
Gunning for the Leaders Hepatitis C drugs take center stage. mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? mark for My Articles similar articles
The Motley Fool
July 27, 2011
Brian Orelli
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. mark for My Articles similar articles
The Motley Fool
June 14, 2011
Brian Orelli
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. mark for My Articles similar articles
The Motley Fool
October 2, 2009
Brian Orelli
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. mark for My Articles similar articles
The Motley Fool
May 5, 2010
Brian Orelli
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. mark for My Articles similar articles
The Motley Fool
April 26, 2011
Brian Orelli
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. mark for My Articles similar articles
The Motley Fool
August 11, 2010
Brian Orelli
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. mark for My Articles similar articles
The Motley Fool
October 31, 2011
Brian Orelli
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... mark for My Articles similar articles
The Motley Fool
May 18, 2009
Brian Orelli
Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship. mark for My Articles similar articles
The Motley Fool
September 8, 2010
Brian Orelli
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. mark for My Articles similar articles
The Motley Fool
September 7, 2007
Brian Orelli
Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications. mark for My Articles similar articles
The Motley Fool
July 15, 2010
Brian Orelli
The Blockbuster Drug Survives Another Body Blow Avandia is still standing. mark for My Articles similar articles
The Motley Fool
December 5, 2007
Brian Orelli
Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious? mark for My Articles similar articles
The Motley Fool
November 24, 2010
Brian Orelli
Profit From the United States of Diabetes Half the country could have an early form by 2020. mark for My Articles similar articles
The Motley Fool
January 19, 2012
Brian Orelli
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. mark for My Articles similar articles
The Motley Fool
April 17, 2007
Brian Lawler
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. mark for My Articles similar articles
The Motley Fool
April 29, 2008
Brian Orelli
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. mark for My Articles similar articles
The Motley Fool
July 27, 2011
Alexander Crawford
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? mark for My Articles similar articles
The Motley Fool
July 18, 2008
Brian Orelli
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. mark for My Articles similar articles
The Motley Fool
November 25, 2011
Dan Caplinger
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. mark for My Articles similar articles
The Motley Fool
April 30, 2011
Brian Orelli
No Long-Term Guidance? No Problem! Looking good, Merck. mark for My Articles similar articles
The Motley Fool
April 25, 2011
Luke Timmerman
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? mark for My Articles similar articles
The Motley Fool
June 22, 2004
Charly Travers
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. mark for My Articles similar articles
The Motley Fool
April 24, 2009
Brian Orelli
Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters. mark for My Articles similar articles
The Motley Fool
August 23, 2004
Ben McClure
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. mark for My Articles similar articles
The Motley Fool
January 21, 2011
Brian Orelli
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. mark for My Articles similar articles
The Motley Fool
February 20, 2008
Brian Orelli
Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note. mark for My Articles similar articles
The Motley Fool
November 2, 2011
David Williamson
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. mark for My Articles similar articles
BusinessWeek
July 26, 2004
Amy Barrett
Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents? mark for My Articles similar articles
The Motley Fool
January 31, 2007
Brian Lawler
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. mark for My Articles similar articles